New hope for ITP patients: Head-to-Head drug trial launches
Disease control
Not yet recruiting
This study tests two second-line treatments for immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. About 220 adults who did not improve with first-line steroids will receive either Avatrombopag (a daily pill that boosts …
Phase: PHASE3 • Sponsor: Ostfold Hospital Trust • Aim: Disease control
Last updated May 17, 2026 10:05 UTC